ClinicalTrials.gg

Program

batoclimab

Also written as “Batoclimab”, “Batoclimab 340 mg SC weekly” and “HBM9161 Injection (680mg)”.

Its studies are mostly in Graves Ophthalmopathy · Myasthenia Gravis · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Graves Disease · Purpura, Thrombocytopenic, Idiopathic, led by 2 companies.

Furthest: phase 3, since May 26, 202218 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunovant Sciences110 open or runningphase 3since May 26, 2022Feb 20, 2019none ahead
Harbour BioMed (Guangzhou)70 open or runningphase 3since Jun 9, 2020May 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Feb 20, 2019.

  1. Apr 17, 2019Phase 2 study in Graves OphthalmopathyImmunovant Sciences · NCT03922321 · 7 enrolled · Canada
  2. May 1, 2019Phase 2 study in Graves OphthalmopathyImmunovant Sciences · NCT03938545 · 65 enrolled · United States, Canada, Germany and more
  3. May 30, 2019Harbour BioMed (Guangzhou)'s first study: phase 1 study in Healthy Chinese VolunteersNew to Harbour BioMed (Guangzhou)Harbour BioMed (Guangzhou) · NCT03971916 · 24 enrolled · China
  4. Nov 21, 2019Phase 1 study in Neuromyelitis OpticaHarbour BioMed (Guangzhou) · NCT04227470 · 9 enrolled · China
  5. Jan 21, 2020Phase 2 study in Warm Autoimmune Hemolytic AnemiaImmunovant Sciences · NCT04253236 · 5 enrolled · United States, Israel, Korea, Republic of and more
  6. Apr 13, 2020Phase 2 study in Myasthenia GravisHarbour BioMed (Guangzhou) · NCT04346888 · 30 enrolled · China
  7. Jun 9, 2020Phase 3 study in Primary Immune Thrombocytopenic PurpuraHarbour BioMed (Guangzhou) · NCT04428255 · 36 enrolled · China
  8. Aug 3, 20212 phase 3 studiesHarbour BioMed (Guangzhou) · NCT05015127, NCT05039190
  9. Apr 6, 2022Phase 3 study in Myasthenia GravisHarbour BioMed (Guangzhou) · NCT05332210 · 111 enrolled · China
  10. May 26, 2022Phase 3 study in Myasthenia GravisImmunovant Sciences · NCT05403541 · 233 enrolled · United States, Argentina, Brazil and more
  11. Aug 24, 20223 phase 3 studies in Graves OphthalmopathyImmunovant Sciences · NCT05524571, NCT05517447, NCT05517421
  12. Oct 12, 2022Phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunovant Sciences · NCT05581199 · 94 enrolled · United States, Argentina, Belgium and more
  13. May 15, 2023Phase 2 study in Graves DiseaseImmunovant Sciences · NCT05907668 · 32 enrolled · Germany
  14. Sep 16, 2025Phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunovant Sciences · NCT07188844 · 26 enrolled · United States, Argentina, Belgium and more

TargetBeta

FCGRT →read by rule
“IgG receptor FcRn large subunit p51 inhibitor”ChEMBL 37, by rule

Other programs on FCGRT

ProgramCompanyFurthest phaseStudies
efgartigimod alfaruleargenxphase 448
rozanolixizumabruleUCBphase 423
nipocalimabruleJohnson & Johnsonphase 324

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07188844Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more2TerminatedImmunovant SciencesJul 16, 202626
NCT05907668Graves Disease · Germany2CompletedImmunovant SciencesJul 25, 202532
NCT05581199Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more2TerminatedImmunovant SciencesJul 20, 202694
NCT05524571Graves Ophthalmopathy · United States, Australia, Belgium and more3CompletedImmunovant SciencesFeb 3, 202686
NCT05517447Graves Ophthalmopathy · United States, Australia, Belgium and more3TerminatedImmunovant SciencesApr 2, 2026109
NCT05517421Graves Ophthalmopathy · United States, Canada, Georgia and more3CompletedImmunovant SciencesNov 2, 2025114
NCT05403541Myasthenia Gravis · United States, Argentina, Brazil and more3TerminatedImmunovant SciencesJan 10, 2025233
NCT05332210Myasthenia Gravis · China3CompletedHarbour BioMed (Guangzhou)Apr 26, 2024111
NCT05039190Myasthenia Gravis · China3CompletedHarbour BioMed (Guangzhou)Jan 14, 2023132
NCT05015127Graves Ophthalmopathy · China3UNKNOWNHarbour BioMed (Guangzhou)Oct 202236
NCT04428255Primary Immune Thrombocytopenic Purpura · China3CompletedHarbour BioMed (Guangzhou)Aug 10, 202136
NCT04346888Myasthenia Gravis · China2CompletedHarbour BioMed (Guangzhou)Aug 24, 202130
NCT04253236Warm Autoimmune Hemolytic Anemia · United States, Israel, Korea, Republic of and more2TerminatedImmunovant SciencesApr 1, 20215
NCT04227470Neuromyelitis Optica · China1CompletedHarbour BioMed (Guangzhou)Dec 3, 20219
NCT03971916Healthy Chinese Volunteers · China1CompletedHarbour BioMed (Guangzhou)Nov 6, 201924
NCT03938545Graves Ophthalmopathy · United States, Canada, Germany and more2TerminatedImmunovant SciencesFeb 2, 202165
NCT03922321Graves Ophthalmopathy · Canada2CompletedImmunovant SciencesFeb 29, 20207
NCT03863080Myasthenia Gravis · United States, Canada2CompletedImmunovant SciencesOct 7, 202017

How it is read

Names in the registry

  • “Batoclimab”, 4 entries
  • “Batoclimab 340 mg SC weekly”, 2 entries
  • “HBM9161 Injection (680mg)”, 2 entries
  • “RVT-1401”, 2 entries
  • “Batoclimab 680 mg SC weekly”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.